Drug details

Rybelsus (semaglutide tablets)

type of Antidiabetics, Glucagon-like Peptide-1 Agonists

Rybelsus (semaglutide) is a glucagon-like peptide-1 (GLP-1) receptor agonist indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.

This drug may have the following side effects:
  • hives,
  • nausea,
  • rash,
  • vomiting,
  • fever,
  • pale skin,
  • lightheadedness,
  • shortness of breath,
  • confusion,
  • chills,
  • fast heartbeats,
  • stomach pain,
  • chest pain,
  • blurred vision,
  • coughing,
  • fatigue,
  • nervousness,
  • sweating,
  • weakness,
  • trouble swallowing,
  • headaches,
  • hoarseness,
  • irregular heartbeat,
  • seizures,
  • anxiety,
  • irritability,
  • decreased urination,
  • hunger,
  • nightmares,
  • coordination difficulties,
  • sudden vision loss,
  • sleepiness,
  • eye pain or redness,
  • neck pain,
  • difficulty breathing
  • clamminess,
  • impatience,
  • swelling in your legs, ankles, or feet,
  • a lump on the front of the neck,
  • upper stomach pain that radiates to your back,
  • stomach pain that feels worse after eating,
  • floaters in your field of vision,
  • gradually worsening vision,
  • feeling shaky,
  • tingling or numbness in the lips, tongue, or cheeks,
  • swelling of your face, tongue or throat, and
The following drugs are related to Rybelsus, either as a replacement or used together:
  • Actos (pioglitazone hydrochloride)
  • Amaryl Tablets (glimepiride)
  • Baqsimi (glucagon nasal powder)
  • Brenzavvy (bexagliflozin tablets)
  • Invokana (canagliflozin tablets)
  • Trulicity (dulaglutide injection, for subcutaneous use)
  • Jardiance (empagliflozin tablets)
  • Tresiba (insulin degludec injection)
  • Januvia (sitagliptin phosphate)
  • Tradjenta (linagliptin)
  • Saxenda (liraglutide [rdna origin]) injection)
  • Ozempic (semaglutide injection)